Inotiv (NASDAQ:NOTV) (NASDAQ: NOTV) is a contract research organization (CRO) providing integrated drug discovery, nonclinical development and bioanalytical services to the pharmaceutical, biotechnology and life sciences industries. The company’s offerings span in vivo and in vitro pharmacology, toxicology, pathology and safety assessment, supporting clients through the full spectrum of preclinical development. With origins dating back to industry pioneers in laboratory animal sciences and research services, Inotiv has grown through strategic acquisitions and organic expansion to deliver comprehensive solutions under one roof.
Key service lines include behavioral neuroscience, cardiovascular safety pharmacology, toxicokinetics, bioanalysis and pathology. Inotiv’s portfolio is designed to accelerate timelines and reduce complexity for clients by combining GLP-compliant study conduct with robust data management and specialized scientific expertise. The company also offers customized research models, cell-based assays and advanced imaging techniques to address emerging therapeutic areas, such as gene and cell therapies, immuno-oncol ogy and central nervous system disorders.
Operating across multiple facilities in North America, Europe and Asia, Inotiv serves a global customer base ranging from small biotech start-ups to multinational pharmaceutical firms. Its sites maintain rigorous quality standards aligned with FDA, EMA and PMDA guidelines, and are staffed by multidisciplinary teams of veterinary pathologists, pharmacologists, toxicologists and bioanalytical scientists. This international footprint enables Inotiv to support cross-border programs and ensure continuity of service throughout the drug development lifecycle.
Inotiv’s leadership team combines decades of experience in scientific research, regulatory affairs and corporate management. The executive group focuses on strategic growth, operational excellence and client collaboration, aiming to integrate new technologies, expand service capabilities and foster long-term partnerships. Through its end-to-end preclinical platform, Inotiv seeks to streamline development pathways and help clients bring safer, more effective therapies to market.
